Bio-Techne Corp
TECH: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$29.00 | Xlqyrj | Prkkkbvbgk |
Bio-Techne Earnings: In Line Results, Gradual Recovery in Fiscal 2025; Shares Modestly Undervalued
Narrow moat Bio-Techne’s fourth-quarter earnings were in line with our expectations. Revenue was $306 million for the three months and $1.2 billion for the full year ended June 30, which both represented 1% organic year-over-year growth. We are maintaining our fair value estimate of $87 per share and view shares as modestly undervalued.